Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept SC plus methotrexate versus methotrexate alone in early methotrexate-naive rheumatoid arthritis
NL-OMON43711Phase 3Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of abatacept and methotrexate in rheumatoid arthritis (RA) (6 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Primary efficacy endpoint. Planned start Dec 2015; status: withdrawn.
02
Drugs
abataceptmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON43711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43711.